logo
logo
Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc.

NASDAQ•APLS
CEO: Dr. Cedric Francois M.D., Ph.D.
セクター: Healthcare
業種: Biotechnology
上場日: 2017-11-09
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
連絡先情報
100 Fifth Avenue, Waltham, MA, 02451, United States
617-977-5700
www.apellis.com
時価総額
$2.79B
PER (TTM)
61.8
33.3
配当利回り
--
52週高値
$30.48
52週安値
$16.10
52週レンジ
41%
順位61Top 91.5%
2.0
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$458.58M+132.98%
直近4四半期の推移

EPS

$1.71-471.74%
直近4四半期の推移

フリーCF

$108.32M+217.69%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Q3 Revenue Surges 133% Total revenue reached $458.6M for the quarter, driven by $275.0M Sobi upfront payment recognized in licensing revenue.
Net Income Swing Positive Achieved $215.7M net income for Q3 2025, reversing prior year's $57.4M net loss significantly due to revenue recognition.
SYFOVRE/EMPAVELI Sales Nine-month product revenue totaled $499.0M; SYFOVRE sales declined 4% due to increased rebates impacting overall performance.
R&D Spending Decreases Nine-month R&D expenses fell 12% to $221.6M, reflecting lower program-specific external costs across several indications.

リスク要因

Future Funding Requirements Funding needs remain uncertain due to high commercialization costs for EMPAVELI and SYFOVRE; external capital may be required.
SYFOVRE Sales Pressure Product revenue declined 4% year-to-date, facing competitive pressure from oral products and increased rebate utilization.
Credit Facility Covenants Subject to financial covenants, including maintaining $50.0M liquidity if market capitalization falls below $3.0B threshold.
Litigation Uncertainty Continues Securities class action appeal awaits decision; potential liability from ongoing legal claims related to SYFOVRE remains undetermined.

見通し

EMPAVELI Pipeline Expansion Plan to initiate two pivotal trials for EMPAVELI by year-end 2025 targeting FSGS and delayed graft function indications.
Cash Sufficient Twelve Months Current cash position plus anticipated sales expected to fund operations and capital expenditures for at least the next twelve months.
Royalty Agreement Modification Sobi Royalty Agreement reduces royalties by 90% effective July 2025, subject to defined performance-based caps achievement.
New Beam Collaboration Progress Preclinical studies commenced for FcRn gene editing treatment; potential milestones up to $383.8M payable to Beam.

同業比較

売上高 (TTM)

Apellis Pharmaceuticals, Inc.APLS
$1.02B
+42.1%
Legend Biotech CorporationLEGN
$908.96M
+74.7%
Ultragenyx Pharmaceutical Inc.RARE
$630.60M
+20.6%

粗利益率 (最新四半期)

IDEAYA Biosciences, Inc.IDYA
99.5%
+0.0pp
Apellis Pharmaceuticals, Inc.APLS
94.7%
+11.7pp
Agios Pharmaceuticals, Inc.AGIO
87.0%
-4.3pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
CDTX$5.61B-18.6-60.1%0.4%
IMVT$5.22B-10.0-65.8%0.0%
SRRK$4.76B-15.0-122.0%26.7%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
29.2%
高成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい

深度リサーチ

次回決算:2026年2月24日
|
EPS:-$0.39
|
売上高:$199.28M
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年10月30日|
    売上高: $458.58M+133.0%
    |
    EPS: $1.71-471.7%
    予想を上回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年7月31日|
    売上高: $178.49M-10.6%
    |
    EPS: $-0.33+10.0%
    予想通り

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月7日|
    売上高: $166.80M-3.2%
    |
    EPS: $-0.74+37.0%
    予想を下回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月28日|
    売上高: $781.37M+97.0%
    |
    EPS: $-1.60+64.0%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月5日|
    売上高: $196.83M+78.3%
    |
    EPS: $-0.46-60.7%
    予想を下回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月1日|
    売上高: $199.69M+110.3%
    |
    EPS: $-0.30-70.6%
    予想を上回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月7日|
    売上高: $172.33M+284.3%
    |
    EPS: $-0.54-65.4%
    予想を下回る

  • Form 10-K/A - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月29日|
    売上高: $396.59M+425.8%
    |
    EPS: $-4.45+27.6%
    予想を下回る